Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 2 Waldenstrom Macroglobulinemia 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroblastoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Burkitt Lymphoma 1

Interventions

Temozolomide 10 Irinotecan 8 Cyclophosphamide 7 dinutuximab 5 aldesleukin 4 Interleukin-2 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 sargramostim 3 fludarabine 3 Topotecan 3 Melphalan 3 Isotretinoin 3 Filgrastim 3 gallium Ga 68 dotatate 2 Vincristine 2 TPI-287 2 Peripheral Blood Stem Cell Transplantation 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Carboplatin 2 venetoclax 1 trametinib 1 thymoglobulin 1 talazoparib 1 sonidegib 1 silmitasertib 1 plerixafor 1 olaparib 1 naxitamab 1 lutetium Lu 177 dotatate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neuroblastoma × IL32 protein, human × Clear all

NCT04211675 2025-05-13

STING

Nationwide Children's Hospital

Phase 1/2 Recruiting

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡